Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.45 |
| ▸ | F9 | P00740 | 5/20 | 0.39 |
| ▸ | F11 | P03951 | 2/20 | 0.39 |
| ▸ | F7 | P08709 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | ROS1 | P08922 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1232597 | 0.83 | F9 (0.45) | EGFRERBB2F9F11F7 | |
| SCHEMBL9607695 | 0.82 | F9 (0.41) | EGFRERBB2F9F11F7 | |
| SCHEMBL9607660 | 0.79 | F9 (0.56) | EGFRF9F11F7CYP2C9 | |
| SCHEMBL9607690 | 0.77 | F9 (0.46) | EGFRERBB2F9F11F7 | |
| SCHEMBL1232600 | 0.77 | PRKD1 (0.44) | EGFRERBB2F9F11F7 | |
| SCHEMBL9607605 | 0.76 | F9 (0.48) | EGFRERBB2F9F11F7 | |
| SCHEMBL9607696 | 0.75 | F9 (0.48) | EGFRERBB2F9F11F7 | |
| SCHEMBL9607640 | 0.75 | F9 (0.40) | EGFRERBB2F9F11F7 | |
| SCHEMBL9607704 | 0.74 | F9 (0.41) | EGFRERBB2F9F11F7 | |
| SCHEMBL9607702 | 0.70 | EGFR (0.49) | EGFRERBB2CHEK2ROS1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | F9, F8, F12 | EGFR 1037/4885ERBB2 2378/4885F9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.